Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

2019NEX

You are here:Home >> product >> Active Pharmaceutical Ingredients >> Other Active Pharmaceutical Ingredients >> Elvitegravir

Elvitegravir

Elvitegravir

Region: Jiangsu
Minimum Order Quantity:
Monthly Production Capacity:
Send Inquiry Add to Cart
Detailed Description
  • Main Sales Markets: North America, Central/South America, Western Europe, Eastern Europe, Australasia, Asia, Middle East, Africa
  • Sample Provided: no

Elvitegravir (EVG, formerly GS-9137) is an integrase inhibitor used to treat HIV infection. It was developed[1] by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008.[2][3][4] The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild.[5] On September 24, 2014 the FDA approved Elvitegravir (tradename Vitekta) as a single pill formulation.[

Address: Taizhou,Jiangsu,China

City: Taizhou

Contact: Chen Bin

TEL: -523-86818997

Fax: -523-86818697

Send Inquiry
Previous Other Active Pharmaceutical Ingredients Next
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
web对话
live chat
客服对话